Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
On Tuesday, Exact Sciences Corp. (NASDAQ:EXAS) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.
上週二，精密科學公司（納斯達克股票代碼：EXAS）報告了第三季度每股收益虧損0.21美元，相比一年前的盈虧平衡，低於分析師共識虧損預期0.20美元。
The reported quarterly sales of $708.66 million missed the consensus estimate of $717.66 million.
報告的季度銷售額70866萬美元，低於71766萬美元的共識預期。
Screening revenue was $545 million, an increase of 15%, and Precision Oncology's revenue was $164 million, an increase of 5% on a reported and core revenue basis.
篩查營業收入爲54500萬美元，按報告和核心營收基礎上漲15％，而精準腫瘤學的營業收入爲16400萬美元，按報告和核心營收基礎上漲5％。
Also Read: FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test.
另請閱讀：FDA批准精密科學下一代結直腸癌診斷檢測。
"While we have made progress, our execution during the third quarter and updated outlook for the full year don't reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong," said Kevin Conroy, chairman and CEO.
「雖然我們取得了進展，但第三季度的執行情況及全年展望不符合我們的全部潛力。我們計劃在2025年加速增長，我們的長期展望依然強勁，」首席執行官兼董事長凱文・康羅伊表示。
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
預測：精密科學將其2024年營收預測從28.1億美元至28.5億美元下調至27.3億美元至27.5億美元，而共識爲28.32億美元。
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
該指南包括篩查銷售預測爲20.8億—20.95億美元，相比於先前的21.55億—21.75億美元的預測。
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million – $675 million.
精準腫瘤學銷售預計爲65000萬-65500萬美元，低於之前的65500萬–67500萬美元的預測。
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
公司預計2024年調整後的EBITDA爲31000萬—32000萬美元，低於之前33500萬—35500萬美元的指引。
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
William Blair指出，管理層將較低預期指引主要歸因於影響篩查業務的挑戰。
While these explanations are logical, they raise questions about why certain factors weren't identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
儘管這些解釋是合情合理的，但它們引發了爲什麼某些因素沒有更早被確認或解決的問題。但是，管理層完全承擔了責任，並傳達了改善業績的真誠承諾，分析師寫道。
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company's control.
儘管存在這些障礙，分析師對2025年的營收增長保持樂觀態度，強調公司能夠控制的幾個因素。
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
William Blair強調投資者可能希望看到在2025年清晰展現改善執行和恢復營收增長的明顯跡象。
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
隨着股價下跌，該分析師寫道，估值處於具有引人入勝的長期介入點。
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
股票週三最新價爲51.16美元，EXAS股價下跌28.50%。
- Apollo's Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast
- 高盛表示，阿波羅在替代資產中的費用相關盈利增長使其脫穎而出，分析師預測每股收益看好。
譯文內容由第三人軟體翻譯。
